ArticlePain2026
Change in prescription opioid dose and the risk of mental health-related and substance use-related emergency department presentations: a case-crossover study.
Article in Pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
abstractOpioid deprescribing is recommended to reduce opioid-related harms; however, research suggests that opioid dose changes may lead to adverse health outcomes. We aimed to determine if opioid dose changes are associated with mental health-related or substance use-related emergency department (ED) presentations. This self-controlled case-crossover study used POpulation Level Analysis and Reporting (POLAR) primary care data linked with data from 3 metropolitan hospitals in Victoria, Australia. People who had a mental health-related or substance use-related ED (MHSU-ED) presentation between April 2018 and May 2022 and had received ≥4 opioid prescriptions in the 12 months preceding their ED presentation were included. Adjusted odds ratios (aOR) for MHSU-ED presentations were estimated using conditional logistic regression, comparing opioid dose change in the 30 days before MHSU-ED presentation to that in 5 corresponding sets of control periods of equal length not immediately preceding MHSU-ED presentation. Of the 1458 eligible patients, 75.9% experienced a >25% reduction in their prescribed opioid dose in the 30 days before MHSU-ED presentation. Compared with receiving no opioid prescriptions in the 30 days prior, a >25% reduction in prescribed opioid dose (aOR: 1.78; 95% confidence interval [CI]: 1.44-2.21) or opioid discontinuation (aOR: 2.04; 95% CI: 1.48-2.82) was linked to higher odds of a MHSU-ED presentation whilst a 10% to 25% reduction (aOR: 0.15; 95% CI: 0.10-0.23) or a stable or increased dose (aOR: 0.01; 95% CI: 0.008-0.022) was associated with lower odds of MHSU-ED presentation. Larger opioid dose reduction or discontinuation is associated with increased risk of subsequent mental health-related and substance use-related ED presentations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.